Corplex Donepezil Skin Patch Therapy Moves to Phase 1 Trial

Corplex Donepezil Skin Patch Therapy Moves to Phase 1 Trial
A once-weekly transdermal patch delivers the most commonly prescribed treatment for Alzheimer’s disease in a way that is biologically equivalent to taking the medication orally, according to preliminary pilot study results. Corium International conducted the bioequivalence (BE) pilot study on its lead product, Corplex, which delivers donepezil — the same active ingredient found in the orally administrated Aricept

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. THELMA says:

    SOUNDS VERY INTERESTING, BUT CAN IT WORK ON PATIENT WHO HAS ALREADY HAD ALZHEIMERS FOR SOME 12 OR SO YEARS PLEASE..

Leave a Comment

Your email address will not be published. Required fields are marked *